SYNOPSIS Studies with 1251-fibrinogen after the administration of phenformin plus ethyloestrenol in five subjects showed no evidence of enhanced catabolism of fibrinogen despite a fall in plasma fibrinogen concentration and shortened clot lysis time. It seems probable that the fall in plasma fibrinogen concentration after the administration of these drugs is related to diminished hepatic synthesis offibrinogen and is independent of the induction of plasminogen activator release.
It has be-n shown that the combined administration of phenformin and ethyloestrenol produces a sustained increase in the fibrinolytic activity of the blood both in healthy and diseased subjects. Moreover the enhancement of fibrinolysis is associated with a fall in plasma fibrinogen concentration and the temporary appearance in the serum of fibrin degradation products (Fearnley, Chakrabarti, and Hocking, 1967; Fearnley, Chakrabarti, and Evans, 1969) . The association of increased fibrinolytic activity and fall in plasma fibrinogen concentration raises the question whether the lysis of fibrinogen as well as of fibrin is promoted by these drugs.
To pursue this further survival studies with 1251-fibrinogen were performed in four patients and in a fifth healthy subject before and during treatment with phenformin and ethyloestrenol.
Methods

PLAN OF STUDY
1251-fibrinogen survival, plasma fibrinogen concentration, dilute blood clot lysis time, and fibrin degradation products were studied in both the pretreatment and treatment periods.
In the healthy subject phenformin (sustained release capsules) 50 mg twice daily plus ethylReceived for publication 15 May 1970. oestrenol 4 mg twice daily were given five days after the injection of 50 ,uC 1251-fibrinogen. By the fifth day a baseline half-life (T/2) 1251-fibrinogen had been obtained as well as estimations of fibrinogen concentration, blood lysis time, and fibrin degradation products.
In four patients treated with the same dose of phenformin and ethyloestrenol, one month was allowed to elapse before the second period of study since it is known that maximal enhancement of fibrinolytic activity and fall in plasma fibrinogen concentration does not occur until several weeks after treatment is first instituted (Fearnley, Chakrabarti, and Evans, 1966 
Results
The findings are shown in Table I and in Figures  1 and 2.  Table I shows the half life of 1251-fibrinogen (T/2) before and after one month's treatment with phenformin and ethyloestrenol. Plasma fibrinogen concentration, dilute blood clot lysis times, and levels of serum fibrin degradation products are also shown. Figure 1 shows the results from the study of the healthy male subject. 1251-fibrinogen survival is expressed as radioactivity in the clottable fraction as a percentage of the 10-minute sample. It will be noted that the administration of phenformin and ethyloestrenol did not cause any alteration in slope of the curve for 12511 fibrinogen survival, although by the end of the study the blood clot lysis time had been shortened significantly. The slight rise in plasma fibrinogen level after starting the drugs has previously been observed in subjects with normal levels of fibrinogen at the outset of treatment (Fearnley, personal communication) . Figure 2 shows the results from case 2. The 1261-fibrinogen survival is shown before and after one month's treatment. The T/2 has fallen from 116 hours to 100 hours but mathematical analysis of the curves reveals that the fractional catabolic rate is virtually unchanged at 21-2% per day compared with 19-5% per day. Furthermore, in view of the fall in the plasma fibrinogen pool in the second study, the absolute amount of fibrinogen catabolized per day has actually fallen from 3-27 g to 2 31 g per day, a fall of 29%.
Discussion
The values obtained for the half-life of 1251_ fibrinogen in this study are similar to those obtained in healthy subjects by Takeda (1966) , by Regoeczi and Stannard (1969) , and in control subjects with miscellaneous disorders by Baker, Rubenberg, Dacie, and Brain (1968) . This suggests that the 1251-fibrinogen preparation used here was adequate for metabolic purposes.
In this study fibrinogen catabolism was not significantly enhanced after the administration of phenformin and ethyloestrenol despite increased fibrinolytic activity in all the subjects and a fall in the plasma fibrinogen concentration in three of the four patients treated with the drugs for one month.
Similar findings of increased fibrinolysis without change in fibrinogen catabolism were obtained by Regoeczi and Walton (1967) by the consumption of phenformin. However, no NOL 4 mg. bd. change in the plasma fibrinogen concentration 50 mg. bd.
was produced in these short-term experiments.
____--1____
If the fall in plasma fibrinogen concentration after the administration of phenformin and ethyloestrenol is not a reflection of increased catabolism then it would seem likely that the hepatic synthesis of fibrinogen is decreased. Such a decrease is unlikely to be related to the fibrinolytic activity of these drugs, an effect that is thought to be due to the induction of plasminogen activator release. The independence of these two activities is borne out by the fact that no correlation has ever been observed between enhancement of fibrinolysis and fall in plasma fibrinogen concentration. This dissociation is illustrated in the study of the healthy subject reported here who showed significant shortening of the lysis time despite a rise in the plasma fibrinogen concentration.
Interest in phenformin and ethyloestrenol is chiefly centred on their effect upon the fibrinolytic mechanism. However, alterations in the plasma 5'/2 6 4"2 5 fibrinogen concentration will affect those tests of fibrinolysis which use the subject's own fibrinogen as the stroma for the test. Thus Gallimore and
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